CD79A and colorectal cancer: Similarly, serum anti-FadAc IgA titers from study 2 were also found to be significantly increased in patients with colorectal cancer compared with those with advanced adenomas (2.06 ± 1.47 μg/mL vs. 1.49 ± 0.99 μg/mL, P = 0.025; Fig. 2A).